To include your compound in the COVID-19 Resource Center, submit it here.
In a double-blind, 6-month U.S. Phase III trial (study 105) in 527 patients with dry eye, INS365 2% ophthalmic drops
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury